当前位置： SCI文献检索 > CANCER CHEMOTHERAPY AND PHARMACOLOGY期刊下所有文献 > Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.

Abstract：

PURPOSE:Although anthracycline is a key agent in breast cancer treatment, its use is associated with the risk of cardiotoxicity. Recently, the value of combination therapy with docetaxel and cyclophosphamide was reported. Because the characteristics of paclitaxel differ on weekly versus tri-weekly administration, such as in the induction of apoptosis and anti-angiogenic activity, establishment of a treatment regimen with a combination of paclitaxel and cyclophosphamide (PC) is warranted. We initiated a phase I study to determine the maximum tolerated dose (MTD) and recommended dose (RD) of combination therapy with PC for advanced or recurrent breast cancer. PATIENTS AND METHODS:Eligible patients had advanced or recurrent breast cancer. Paclitaxel was given intravenously on days 1, 8, and 15 of every 3-week course, and cyclophosphamide on day 1, over a total of four courses. Paclitaxel was given at 80 mg/m(2) for level 1 and 100 mg/m(2) for level 2, and cyclophosphamide at 600 mg/m(2) in both cases. Onset of dose-limiting toxicity was evaluated during the first course, and tolerability throughout the four courses. RESULTS:Four patients were enrolled in each of levels 1 and 2 from October 2006 to November 2007. The main toxicities were grade 3 neutropenia in four patients (50%) and sensory neuropathy in one (12.5%). An MTD was not attained, as neither a hematologic toxicity of grade 4 nor a non-hematologic toxicity of grade 3 or higher was observed during the first course at level 1 or 2. Response rate amongst assessable patients (one in level 1, two in level 2) was 66.7%. CONCLUSIONS:Safety was well tolerated throughout the four courses at level 2, and this dosage level was therefore regarded as the RD.

journal_name

Cancer Chemother Pharmacol

journal_title

Cancer chemotherapy and pharmacology

authors

Masuda N,Nakayama T,Yamamura J,Kamigaki S,Taguchi T,Hatta M,Sakamoto J

doi

10.1007/s00280-009-1137-z

subject

Has Abstract

pub_date

2010-05-01 00:00:00

pages

89-94

issue

eissn

0344-5704

issn

1432-0843

journal_volume

pub_type

杂志文章,多中心研究

在线工具

Phase I study of combination therapy with weekly paclitaxel and cyclophosphamide for advanced or recurrent breast cancer.